← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. (2019/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia. (2019/05/01) ♡
• Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. (2019/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A confusing 'white cell count': Circulating micromegakaryocytes in post-thrombocythemia myelofibrosis. (2019/05/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. (2019/05/01) ♡
• Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. (2019/04/11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. (2019/04/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. (2019/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Osteoradionecrosis of the sternoclavicular joint after laryngopharyngeal radiation. (2019/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. (2019/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. (2019/04/01) ♡
• Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. (2019/04/01) ♡
• Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. (2019/04/01) ♡
• Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms. (2019/04/01) ♡
• Erratum to correct 'How we approach: Severe congenital neutropenia and myelofibrosis due to mutations in VPS45'. (2019/04/01) ♡
• Chromosome 12 Rearrangement in an Adolescent with Primary Myelofibrosis. (2019/04/01) ♡
• Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. (2019/03/01) ♡
• Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. (2019/03/01) ♡
• Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. (2019/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Singular case of osteolytic lesions revealing transformation of myeloproliferative syndrome to acute leukemia. (2019/03/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all. (2019/03/01) ♡
• The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. (2019/03/01) ♡
• 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. (2019/03/01) ♡
• WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. (2019/03/01) ♡
• Outcome of Childhood Acute Megakaryoblastic Leukemia: Children's Cancer Hospital Egypt 57357 Experience. (2019/03/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. (2019/03/01) ♡
• Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2(V617F) against myeloproliferative neoplasms. (2019/02/04) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treating early-stage myelofibrosis. (2019/02/01) ♡
• Adolescent and Young Adult Chronic Myeloid Leukemia in Real-World Settings: Experience from a Tertiary Care Institute in Northern India. (2019/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality. (2019/01/09) ♡
• Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. (2019/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Heterogeneity in myeloproliferative neoplasms: Causes and consequences. (2019/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Genetic studies in the evaluation of myeloproliferative neoplasms. (2019/01/01) ♡
• Myeloid Sarcoma with Megakaryoblastic Differentiation Arising in the Conjunctiva. (2019/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms]. (2019/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria. (2019/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel treatment strategies for myeloproliferative neoplasms. (2019/01/01) ♡
• [Interferon-alpha in the treatment of myeloproliferative diseases]. (2019/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. CC-4047 in Treating Patients With Myelofibrosis (2019-12-30) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. iCare for Cancer Patients (2019-12-20) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) (2019-12-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases (2019-12-03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia (2019-11-20) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant (2019-11-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (2019-11-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (2019-10-30) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (2019-10-21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source (2019-10-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes (2019-10-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (2019-09-24) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.